Loading stock data…
Loading stock data…
US$4.72
Get one email when AVIR crosses your level. Checked every 15 minutes during market hours.
▼ -0.14 (-2.98%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
50.8
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.07
Bullish momentumMACD above its signal line (0.06).
50-day average
4.62
Price aboveShort-term trend reference.
200-day average
4.25
Price aboveLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its variants. The company is also advancing bemnifosbuvir in combination with ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment, with this regimen currently in Phase 3 clinical tr…
ateapharma.com3 strong buy · 4 buy · 2 hold · 0 sell · 0 strong sell (9 analysts, 2026-07-01)
3 strong buy · 4 buy · 2 hold · 0 sell · 0 strong sell (9 analysts, 2026-06-01)
3 strong buy · 4 buy · 2 hold · 0 sell · 0 strong sell (9 analysts, 2026-05-01)
3 strong buy · 4 buy · 2 hold · 0 sell · 0 strong sell (9 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-07-16 | 1.1 | 1.17 | ✓ Beat |
| 2026-04-30 | 2.03 | 2.68 | ✓ Beat |
| 2026-03-05 | -0.48 | -0.57 | ✗ Miss |
| 2026-01-13 | 1.36 | 1.52 | ✓ Beat |
| 2025-11-12 | -0.41 | -0.53 | ✗ Miss |
| 2025-10-14 | 0.45 | 0.51 | ✓ Beat |
| 2025-09-10 | -0.16 | -0.31 | ✗ Miss |
Companies in the same industry, via Finnhub